

Iain A Mcneish

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6887303/iain-a-mcneish-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

13,975
citations

44
h-index

117
g-index

187
ext. papers

17,142
ext. citations

9.3
avg, IF

5.4
L-index

#	Paper	IF	Citations
163	Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers.. <i>ESMO Open</i> , 2022 , 7, 100401	6	0
162	The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.. <i>Clinical Cancer Research</i> , 2022 , OF1-OF12	12.9	1
161	Risk Factors for Ovarian Cancer: An Umbrella Review of the Literature. <i>Cancers</i> , 2022 , 14, 2708	6.6	1
160	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 217-228	4	7
159	European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer. <i>Annals of Oncology</i> , 2021 ,	10.3	7
158	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021 ,	13.4	6
157	Structural Variants at the Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3201-3214	12.9	1
156	Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. <i>Oncogene</i> , 2021 , 40, 3665-3679	9.2	2
155	The Emerging Role of Interleukin 1 β (IL-1 β) in Cancer Cachexia. <i>Inflammation</i> , 2021 , 44, 1223-1228	5.1	5
154	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021 , 12, 2487	17.4	24
153	Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5530-5530	2.2	1
152	Metronomic oral cyclophosphamide in relapsed ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1037-1044	3.5	2
151	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021 , 161, 668-675	4.9	0
150	Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells. <i>Viruses</i> , 2021 , 13,	6.2	2
149	Characterization of a -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021 , 3, zcab028	5.2	4
148	Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 277-288	21.7	9
147	Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 161-168	3.5	9

146	FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 176-186	5.2	1
145	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. <i>Cell Reports</i> , 2021 , 36, 109412	10.6	12
144	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1589-1594	3.5	6
143	Activating a collaborative innate-adaptive immune response to control metastasis. <i>Cancer Cell</i> , 2021 , 39, 1361-1374.e9	24.3	18
142	722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA). <i>Annals of Oncology</i> , 2021 , 32, S725-S726	10.3	4
141	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 163, 490-497	4.9	3
140	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102294	14.4	2
139	Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial 2021 , 9,		2
138	Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis. <i>Cancer Immunology Research</i> , 2020 , 8, 1099-1111	12.5	26
137	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 819-824	3.5	3
136	Prognostic gene expression signature for high-grade serous ovarian cancer. <i>Annals of Oncology</i> , 2020 , 31, 1240-1250	10.3	37
135	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423	12.9	21
134	Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920921980	5.4	1
133	Prophylactic Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models. <i>Cancer Research</i> , 2020 , 80, 549-560	10.1	8
132	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020 , 21, 969-977	21.7	13
131	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11217	12	13
130	Oncologist-led BRCA QmainstreamingQn the ovarian cancer clinic: A study of 255 patients and its impact on their management. <i>Scientific Reports</i> , 2020 , 10, 3390	4.9	13
129	NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020 , 16, 289-301	6.4	18

128	Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. <i>Cell Reports</i> , 2020 , 30, 481-496.e6	10.6	55
127	Organoid models in gynaecological oncology research. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102103	14.4	7
126	Progression-free survival in the ICON8 trial - Authors Reply. <i>Lancet, The</i> , 2020 , 396, 757	4.0	0
125	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019 , 154, 441-448	4.9	39
124	ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019 , 30, 672-705	10.3	298
123	ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019 ,	3.5	71
122	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019 , 8,	7.9	4
121	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, -mutated, high-grade ovarian cancer, and an update on safety. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 1396-1404	3.5	11
120	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 2084-2095	4.0	88
119	Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	2
118	Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019 , 9, 210-219	24.4	142
117	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 505-517	10.1	28
116	Targeting DNA repair: the genome as a potential biomarker. <i>Journal of Pathology</i> , 2018 , 244, 586-597	9.4	28
115	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018 , 47, 450-459	7.8	8
114	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018 , 78, 5419-5430	10.1	32
113	Neoantigens in Ovarian Cancer: Embarrassment of Riches or Needles in a Haystack?. <i>Clinical Cancer Research</i> , 2018 , 24, 5493-5495	12.9	2
112	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018 , 13, e0197561	3.7	9
111	Copy number signatures and mutational processes in ovarian carcinoma. <i>Nature Genetics</i> , 2018 , 50, 1262-1270	16.7	155

110	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	3
109	Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5545-5545	2.2	2
108	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. <i>Oncotarget</i> , 2018 , 9, 4722-4736	3.3	13
107	Mannose impairs tumour growth and enhances chemotherapy. <i>Nature</i> , 2018 , 563, 719-723	50.4	152
106	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology, The</i> , 2018 , 19, 1680-1687	21.7	105
105	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018 , 9, 3970	17.4	111
104	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017 , 116, 524-535	8.7	18
103	Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. <i>Nature Communications</i> , 2017 , 8, 14206	17.4	50
102	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 75-87	21.7	706
101	Secondary Somatic Mutations Restoring and Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017 , 7, 984-998	24.4	193
100	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
99	Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). <i>European Journal of Cancer</i> , 2017 , 72, S95	7.5	2
98	Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROc consortium. <i>British Journal of Cancer</i> , 2017 , 116, 1294-1301	8.7	7
97	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , 2017 , 28, 459-468	2.8	13
96	The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma. <i>Clinical Cancer Research</i> , 2017 , 23, 7633-7640	12.9	13
95	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017 , 147, 267-275	4.9	163
94	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 1949-1961	40	815
93	Oncolytic virus-induced cell death and immunity: a match made in heaven?. <i>Journal of Leukocyte Biology</i> , 2017 , 102, 631-643	6.5	27

92	Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2. <i>Gynecologic Oncology</i> , 2017 , 145, 2	4.9	27
91	RIPK3 promotes adenovirus type 5 activity. <i>Cell Death and Disease</i> , 2017 , 8, 3206	9.8	12
90	CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. <i>Scientific Reports</i> , 2017 , 7, 16827	4.9	34
89	BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1. <i>Gynecologic Oncology</i> , 2017 , 145, 5	4.9	11
88	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 420-424	4	3
87	Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. <i>Annals of Oncology</i> , 2017 , 28, 702-710	10.3	32
86	A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2594-2594	2.2	1
85	OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer with olaparib (AZD2375) or niraparib (AZD5363).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5609-TPS5609	2.2	1
84	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
83	CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. <i>Cancer Research</i> , 2016 , 76, 6118-6129	10.1	83
82	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	24.4	104
81	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
80	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 3025-36	12.9	80
79	The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. <i>Current Biology</i> , 2016 , 26, 755-65	6.3	44
78	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
77	RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2016 , 14, 44-55	6.6	12
76	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5540-5540	2.2	16
75	A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5543-5543	2.2	2

74	Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5549-5549	2.2	8
73	NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear-cell carcinoma of the ovary or endometrium.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS5603-TPS5603	2.2	3
72	TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS5604-TPS5604	2.2	1
71	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016 , 7, 72381-72394	3.3	11
70	Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus. <i>Gene Therapy</i> , 2015 , 22, 476-84	4	17
69	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1574-84	4	24
68	Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: Interim results for ARIEL2 clinical trial. <i>Gynecologic Oncology</i> , 2015 , 138, 4	4.9	5
67	Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. <i>Molecular Oncology</i> , 2015 , 9, 791-805	7.9	24
66	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. <i>Gynecologic Oncology</i> , 2015 , 136, 542-8	4.9	12
65	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015 , 36, 1341-53	4.6	20
64	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 668-79	31.3	581
63	Pharmacological Inhibition of β Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. <i>Cancer Research</i> , 2015 , 75, 2811-21	10.1	9
62	2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. <i>European Journal of Cancer</i> , 2015 , 51, S531-S532	7.5	11
61	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015 , 10, e0128106	3.7	15
60	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5508-5508	2.2	52
59	A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS5611-TPS5611	2.2	1
58	Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges for biomarker-directed therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5539-5539	2.2	
57	Routine germline BRCA testing in serous ovarian cancer: The West of Scotland experience.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16532-e16532	2.2	

56	Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume. <i>Clinical Cancer Research</i> , 2014 , 20, 2751-60	12.9	36
55	ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal	2.2	3
54	ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5619-TPS5619	2.2	8
53	Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. <i>FASEB Journal</i> , 2013 , 27, 4244-53	0.9	16
52	Clear cell carcinoma of ovary and uterus. <i>Current Oncology Reports</i> , 2013 , 15, 566-72	6.3	25
51	Targeted anti-vascular therapies for ovarian cancer: current evidence. <i>British Journal of Cancer</i> , 2013 , 108, 250-8	8.7	58
50	Vaccinia virus induces programmed necrosis in ovarian cancer cells. <i>Molecular Therapy</i> , 2013 , 21, 2074-86	11.7	45
49	Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. <i>Molecular Therapy</i> , 2012 , 20, 1676-88	11.7	25
48	Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. <i>Cancer Research</i> , 2012 , 72, 1342-52	10.1	28
47	The peritoneal tumour microenvironment of high-grade serous ovarian cancer. <i>Journal of Pathology</i> , 2012 , 227, 136-45	9.4	41
46	Paraneoplastic thrombocytosis in ovarian cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 610-8	59.2	505
45	Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. <i>Oncotarget</i> , 2012 , 3, 78-83	3.3	26
44	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011 , 11, 719-25	31.3	893
43	The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. <i>Biomaterials</i> , 2011 , 32, 8538-47	15.6	13
42	Inhibition of the inflammatory cytokine TNF- α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. <i>Molecular Therapy</i> , 2011 , 19, 490-9	11.7	17
41	Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3798-804	2.2	182
40	Interleukin-6 as a therapeutic target in human ovarian cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 6083-96	12.9	291
39	IL-6 and Ovarian Cancer Response. <i>Clinical Cancer Research</i> , 2011 , 17, 7838-7838	12.9	2

38	Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. <i>Cancer Research</i> , 2011 , 71, 3317-27	10.1	46
37	Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1283-97	15.9	22
36	Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. <i>Clinical Cancer Research</i> , 2010 , 16, 4005-13	12.9	189
35	Tropism-modification strategies for targeted gene delivery using adenoviral vectors. <i>Viruses</i> , 2010 , 2, 2290-355	6.2	95
34	p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. <i>Molecular Cancer</i> , 2010 , 9, 175	42.1	14
33	Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1377-85	8.8	32
32	Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. <i>International Journal of Cancer</i> , 2010 , 126, 2762-72	7.5	232
31	In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. <i>Journal of Virology</i> , 2009 , 83, 6416-28	6.6	57
30	Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2009 , 116, 1225-41	3.7	11
29	Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. <i>Future Oncology</i> , 2009 , 5, 339-57	3.6	6
28	A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008 , 115, 808-10	3.7	18
27	Author response to: A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008 , 115, 1586-1587	3.7	
26	Author response to: A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008 , 115, 1714-1714	3.7	
25	"Re-educating" tumor-associated macrophages by targeting NF-kappaB. <i>Journal of Experimental Medicine</i> , 2008 , 205, 1261-8	16.6	630
24	Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. <i>Cancer Research</i> , 2008 , 68, 7923-31	10.1	38
23	Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. <i>International Journal of Cancer</i> , 2007 , 120, 2344-52	7.5	114
22	A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. <i>Clinical Cancer Research</i> , 2006 , 12, 6737-47	12.9	437
21	Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. <i>Cancer Research</i> , 2006 , 66, 989-98	10.1	47

20	Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3Qdeoxy-3Q[18F]fluorothymidine positron emission tomography imaging. <i>Cancer Research</i> , 2006 , 66, 9178-85	10.1	22
19	Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4862-6	2.2	119
18	Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo. <i>International Journal of Molecular Medicine</i> , 2006 , 17, 841-7	4.4	3
17	Survivin: a protein with dual roles in mitosis and apoptosis. <i>International Review of Cytology</i> , 2005 , 247, 35-88		134
16	Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. <i>Molecular and Cellular Biology</i> , 2003 , 23, 7600-10	4.8	98
15	Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. <i>International Journal of Cancer</i> , 2003 , 104, 104-12	7.5	21
14	Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. <i>Oncogene</i> , 2003 , 22, 3539-47	9.2	35
13	Doppler ultrasonography of the uterine artery and the response to chemotherapy in patients with gestational trophoblastic tumors. <i>Clinical Cancer Research</i> , 2002 , 8, 1142-7	12.9	24
12	Twenty-five years clinical experience with placental site trophoblastic tumors. <i>Journal of reproductive medicine, The</i> , 2002 , 47, 460-4		85
11	Management of brain metastases in patients with high-risk gestational trophoblastic tumors. <i>Journal of reproductive medicine, The</i> , 2002 , 47, 465-71		46
10	Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. <i>Cell Death and Differentiation</i> , 2001 , 8, 256-64	12.7	31
9	Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. <i>International Journal of Cancer</i> , 2000 , 86, 848-54	7.5	63
8	Visualization of cardiac emboli from mitral valve papillary fibroelastoma. <i>Stroke</i> , 1996 , 27, 1133-4	6.7	10
7	Oncolytic viral gene therapy in ovarian cancer139-152		
6	Consensus views arising from the 60th Study Group: Gynaecological Cancers: Biology and therapeutics245-248		
5	Pathological Chemotherapy Response Score Predicts Survival in Patients with Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis of Individual Patient Data. <i>SSRN Electronic Journal</i> ,	1	2
4	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
3	Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development		1

2	Copy-number signatures and mutational processes in ovarian carcinoma	3
1	Activating a collaborative innate-adaptive immune response to control breast and ovarian cancer metastasis	2